innovation for industry
Articles ＆ files | Focus | Article | Health ＆ life sciences
Intracerebral Optical Device
Slowing down Parkinson’s disease
using intracranial photobiomodulation,
ie “light medicine into the brain”
CEA-Leti’s clinical trial aims to slow down neurodegeneration using an intracerebral device which generates an emission of a neuro-protecting light. Current treatments for Parkinson’s disease temporarily mitigate symptoms. The therapeutic effects of photobiomodulation have been demonstrated in rodent and non-human primate models of Parkinson’s disease. CEA-Leti's clinical trial aims, in particular, to prove the feasibility, safety and their effectiveness in humans.
The optical unit were developed by CEA-Leti, then manufactured, assembled, and characterized in its clean rooms. The clinical trial patients (Ev-NIRT, driven by Grenoble University Hospital) were implanted at CLINATEC, the CEA-Leti biomedical research center, equipped with a clinical sector with an operating room.
• Treatment for Parkinson’s disease
• Adaptation to other neurodegenerative pathologies, such as Alzheimer’s disease, may be possible
• 10 years of technological development
• 14 patents
• 6.3 million people living withParkinson’s disease worldwide
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.